172 related articles for article (PubMed ID: 17663676)
1. Post-transplant lymphoproliferative disease in children following solid organ transplant and rituximab--the final answer?
Gross TG
Pediatr Transplant; 2007 Sep; 11(6):575-7. PubMed ID: 17663676
[No Abstract] [Full Text] [Related]
2. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
Svoboda J; Kotloff R; Tsai DE
Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
[TBL] [Abstract][Full Text] [Related]
3. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab.
Gallego S; Llort A; Gros L; Sanchez de Toledo J; Bueno J; Moreno A; Nieto J; Sanchez de Toledo J
Pediatr Transplant; 2010 Feb; 14(1):61-6. PubMed ID: 19344338
[TBL] [Abstract][Full Text] [Related]
5. Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation.
Kaczmarek I; Beiras-Fernandez A; Sadoni S; Bengel D; Deutsch MA; Meiser B; Reichart B
Exp Clin Transplant; 2005 Dec; 3(2):381-4. PubMed ID: 16417448
[TBL] [Abstract][Full Text] [Related]
6. PTLD treatment: reducing the chemotherapy burden through addition of rituximab.
Dharnidharka VR; Gupta S
Pediatr Transplant; 2010 Feb; 14(1):10-1. PubMed ID: 20078838
[No Abstract] [Full Text] [Related]
7. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
Lee JJ; Lam MS; Rosenberg A
Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
[TBL] [Abstract][Full Text] [Related]
8. Posttransplant lymphoproliferative disorder.
Everly MJ; Bloom RD; Tsai DE; Trofe J
Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.
Trahair TN; Wainstein B; Manton N; Bourne AJ; Ziegler JB; Rice M; Russell SJ
Pediatr Blood Cancer; 2008 Feb; 50(2):366-9. PubMed ID: 16732583
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for PTLD of the CNS: is it a 'no-brainer'?
Reshef R; Tsai DE
Onkologie; 2008 Dec; 31(12):650-1. PubMed ID: 19060501
[No Abstract] [Full Text] [Related]
13. Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder.
Francescone SA; Murphy B; Fallon JT; Hammond K; Pinney S
Transplant Proc; 2009 Jun; 41(5):1946-8. PubMed ID: 19545762
[TBL] [Abstract][Full Text] [Related]
14. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy.
Al-Akash SI; Al Makadma AS; Al Omari MG
Pediatr Transplant; 2005 Apr; 9(2):249-53. PubMed ID: 15787802
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disorders.
Chetty R; Dada MA
S Afr J Surg; 1998 Feb; 36(1):4, 6, 8-9. PubMed ID: 9601824
[No Abstract] [Full Text] [Related]
16. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
[TBL] [Abstract][Full Text] [Related]
17. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines.
Parker A; Bowles K; Bradley JA; Emery V; Featherstone C; Gupte G; Marcus R; Parameshwar J; Ramsay A; Newstead C;
Br J Haematol; 2010 Jun; 149(5):693-705. PubMed ID: 20408848
[TBL] [Abstract][Full Text] [Related]
18. Post transplant lymphoproliferative disease: detection of tumor by Tc99m sestaMIBI and treatment with rituximab.
Paydas S; Yapar Z; Ergin M; Guney IB; Disel U; Yavuz S
Bone Marrow Transplant; 2005 Feb; 35(3):317-8. PubMed ID: 15592492
[No Abstract] [Full Text] [Related]
19. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation.
Pescovitz MD
Pediatr Transplant; 2004 Feb; 8(1):9-21. PubMed ID: 15009836
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant lymphoproliferative disorder.
Loren AW; Tsai DE
Clin Chest Med; 2005 Dec; 26(4):631-45, vii. PubMed ID: 16263402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
